Loading…
MULTI-ACTION ACTIFED DRY COUGHS is a brand name for Dextromethorphan. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Multi-Action ACTIFED Dry Coughs is indicated for the symptomatic relief of upper respiratory tract disorders which are benefited by the combination of a nasal decongestant, a histamine H1-receptor antagonist, and an antitussive.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults and children aged 12 years and over: 10 ml every 4 - 6 hours up to four times a day. Not more than 4 doses should be given in any 24 hours. 3) The Elderly: There have been no specific studies of Multi-Action ACTIFED Dry Coughs in the elderly.
Experience has indicated that normal adult dosage is appropriate.
Hepatic dysfunction:
Caution should be exercised when administering Multi-Action ACTIFED Dry Coughs to patients with hepatic impairment.
Renal dysfunction:
Caution should be exercised when administering Multi-Action ACTIFED Dry Coughs to patients with moderate renal impairment. Method of Administration For oral use Multi-Action ACTIFED Dry Coughs may be diluted 1:1 (1 in 2) or 1:3 (1 in 4) with unpreserved Syrup BP.
These dilutions have a shelf life of 4 weeks if stored at 25°C.
Placebo controlled studies with sufficient adverse event data are not available for the combination of dextromethorphan, pseudoephedrine and triprolidine. Adverse drug reactions identified during clinical trials and post-marketing experience with dextromethorphan, pseudoephedrine or the combination of pseudoephedrine and triprolidine or the combination of dextromethorphan and pseudoephedrine are listed below by System Organ Class (SOC).
The frequencies are defined according to the following convention:
Very common ≥1/10 Common ≥1/100 and < 1/10 Uncommon ≥1/1,000 and <1/100 Rare ≥1/10,000 and <1/1,000 Very rare <1/10,000 Not known (cannot be estimated from the available data) ADRs are presented by frequency category based on 1) incidence in adequately designed clinical trials or epidemiology studies, if available, or 2) when incidence cannot be estimated, frequency is listed as ‘Not known’.
4) Psychomotor hyperactivity Eye Disorders Common Vision blurred Cardiac Disorders Rare Not Known Not Known Not Known Palpitations Dysrhythmias Myocardial infarction/myocardial ischaemia Tachycardia Vascular Disorders Rare Not known Hypotension Hypertension Respiratory, Thoracic and Mediastinal Disorders Common Not Known Not Known Not Known Not Known Increased viscosity of bronchial secretion Dry Throat Epistaxis Nasal dryness Respiratory depression Gastrointestinal Disorders Common Common Common Not Known Not Known Not known Not Known Dry mouth Gastrointestinal disorder Nausea Abdominal pain Diarrhoea Ischaemic colitis Vomiting Hepatobiliary Disorders Rare Liver disorder Skin and Subcutaneous Tissue Disorders Not Known Not Known Not Known Not Known Not Known Angioedema Pruritus Rash Severe skin reactions including acute generalised exanthematous pustulosis (AGEP) Urticaria Renal and Urinary Disorders Common Not Known Urinary Retention (in men in whom prostatic enlargement could have been an important predisposing factor Dysuria General Disorders and Administration Site Conditions Not Known Not Known Drug withdrawal syndrome Fatigue Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Multi-Action ACTIFED Dry Coughs may cause drowsiness. This product should not be used to sedate a child. Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, sedatives and tranquilisers.
Use of dextromethorphan with alcohol or other CNS depressants may increase the effects on the CNS and cause toxicity in relatively smaller doses. While taking this product, patients should be advised to avoid alcoholic drinks and consult a healthcare professional prior to taking with central nervous system depressants.
Patients with difficulty in urination and/or enlargement of the prostate, or patients with thyroid disease who are receiving thyroid hormones or patients with a susceptibility to angle- closure should not take this product unless directed by a physician.
If any of the following occur, this product should be stopped: • Hallucinations • Restlessness • Sleep disturbances Severe Skin Reactions: Severe skin reactions such as acute generalized exanthematous pustulosis (AGEP) may occur with pseudoephedrine-containing products.
This acute pustular eruption may occur within the first 2 days of treatment, with fever, and numerous, small, mostly non-follicular pustules arising on a widespread oedematous erythema and mainly localized on the skin folds, trunk, and upper extremities.
Patients should be carefully monitored. If signs and symptoms such as pyrexia, erythema, or many small pustules are observed, administration of this medicine should be discontinued, and appropriate measures taken if needed.
Ischaemic colitis:
Some cases of ischaemic colitis have been reported with pseudoephedrine. Pseudoephedrine should be discontinued, and medical advice sought if sudden abdominal pain, rectal bleeding or other symptoms of ischemic colitis develop. 8). 3).
1. 5). The concomitant use of this product and MAOIs may cause a rise in blood pressure and/or hypertensive crisis. 5). Cardiovascular disease Severe hypertension or uncontrolled hypertension Diabetes mellitus Phaeochromocytoma Hyperthyroidism Closed angle glaucoma Severe acute or chronic kidney disease/renal failure Dextromethorphan, should not be given to patients in, or at risk of developing respiratory failure.
Not to be used in children under the age of 12 years.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Dextromethorphan in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Pseudoephedrine should be discontinued and immediate medical assistance sought if the following symptoms occur: sudden severe headache or thunderclap headache, nausea, vomiting, confusion, seizures and/or visual disturbances. Most reported cases of PRES and RCVS resolved following discontinuation and appropriate treatment.
Caution should be exercised when using the product in the presence of hepatic impairment or moderate to severe renal impairment or in occlusive vascular disease. Patients with the following conditions should not use this product, unless directed by a physician: acute or chronic asthma, a persistent or chronic cough such as occurs with chronic bronchitis or emphysema, or where cough is accompanied by excessive secretions.
This product should be used with caution in atopic children due to histamine release. Drug dependence, tolerance and potential for abuse For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses.
, major depression). Drug withdrawal syndrome The drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations.
Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
Dextromethorphan is metabolised by hepatic cytochrome P450 2D6. The activity of this enzyme is genetically determined. About 10% of the general population are poor metabolisers of CYP2D6. Poor metabolisers and patients with concomitant use of CYP2D6 inhibitors may experience exaggerated and/or prolonged effects of dextromethorphan.
5). Serotonin Syndrome Serotonergic effects, including the development of a potentially life-threatening serotonin syndrome, have been reported for dextromethorphan with concomitant administration of serotonergic agents, such as selective serotonin re-uptake inhibitors (SSRIs), drugs which impair metabolism of serotonin (including monoamine oxidase inhibitors (MAOIs)) and CYP2D6 inhibitors.
Serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. If serotonin syndrome is suspected, treatment with this medicine should be discontinued. This product should not be taken with any other cough and cold medicines.
This medicine contains 208 mg of alcohol (ethanol) in each 5 ml. The amount in each 5 ml of this medicine is equivalent to less than 6 ml beer or 3 ml wine. The small amount of alcohol in this medicine will not have any noticeable effects.
This medicine contains 10 mg sodium benzoate (E211) in each 5 ml. Methyl hydroxybenzoate (E218) may cause allergic reactions (possibly delayed). The colouring in this medicine (Ponceau 4R, E124) may cause allergic reactions. 8 g of sucrose per 5 ml.
This should be taken into account in patients with diabetes mellitus. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, that is to say essentially ‘sodium-free’. This medicine contains 1 g sorbitol in each 5 ml. The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary […]